

**I/We Claim:**

1. A medicament comprising an antagonist of a Programmed Death 1 protein (PD-1) for use in combination with a vascular endothelial growth factor receptor (VEGFR) inhibitor for treating a cancer in an individual, wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO:21 and SEQ ID NO:22, respectively, and further wherein the VEGFR inhibitor is N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide or a pharmaceutically acceptable salt thereof.
2. A medicament comprising a vascular endothelial growth factor receptor (VEGFR) inhibitor for use in combination with an antagonist of a Programmed Death 1 protein (PD-1) for treating a cancer in an individual, wherein the VEGFR inhibitor is N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide or a pharmaceutically acceptable salt thereof, and further wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO:21 and SEQ ID NO:22.
3. The medicament as claimed in claim 1 or 2, wherein the individual is a human.
4. The medicament as claimed in any one of claims 1 to 3, wherein the cancer is a solid tumor that tests positive for Programmed Death-Ligand 1 (PD-L1) expression by an immunohistochemical (IHC) assay.
5. The medicament of any as claimed in claims 1 to 3, wherein the cancer is renal cell carcinoma.
6. The medicament as claimed in any one of claims 1 to 5, wherein the PD-1 antagonist is pembrolizumab and the VEGFR inhibitor is axitinib.

7. The medicament as claimed in claim 6, wherein the pembrolizumab is formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab, 7% (w/v) sucrose, 0.02% (w/v) polysorbate 80 in 10 mM histidine buffer pH 5.5 and axitinib is formulated as a 1 mg tablet or a 5 mg tablet.

5

8. A kit which comprises a first container, a second container and a package insert, wherein the first container comprises at least one dose of a medicament comprising an antagonist of a Programmed Death 1 protein (PD-1), the second container comprises at least one dose of a medicament comprising a vascular endothelial growth factor receptor (VEGFR) inhibitor, and the package insert comprises instructions for treating an individual for cancer using the medicaments, wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO:21 and SEQ ID NO:22, respectively, and further wherein the VEGFR inhibitor is N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide or a pharmaceutically acceptable salt thereof.

10

15

9. The kit as claimed in claim 8, wherein the instructions state that the medicaments are intended for use in treating an individual having a cancer that tests positive for Programmed Death-Ligand 1 (PD-L1) expression by an immunohistochemical (IHC) assay.

20

10. The kit as claimed in claim 8 or 9, wherein the individual is a human.

11. The kit as claimed in any one of claims 8 to 10, wherein the PD-1 antagonist is pembrolizumab formulated as a liquid medicament and the VEGFR inhibitor is axitinib formulated as a 1 mg tablet or a 5 mg tablet.

25

12. The use or kit as claimed in any one of claims 1-4 or 6-10, wherein the cancer is bladder cancer, breast cancer, clear cell kidney cancer, head/neck squamous cell carcinoma, lung squamous cell carcinoma, malignant melanoma, non-small-cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, small-cell lung cancer

30

(SCLC), triple negative breast cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin's lymphoma (HL), mantle cell lymphoma (MCL), multiple myeloma (MM), myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), non-Hodgkin's lymphoma (NHL), or small lymphocytic lymphoma (SLL).

13. The use or kit as claimed in any one of the above claims, wherein the cancer is advanced renal cell carcinoma.

14. A medicament comprising:

- a) pembrolizumab for use in combination with axitinib for treating a cancer in a human individual by a method comprising administering to the individual (i) axitinib formulated as a 1 mg tablet or a 5 mg tablet and pembrolizumab formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab or (ii) axitinib formulated as a 1 mg tablet or a 5 mg tablet and pembrolizumab formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab; or
- b) axitinib for use in combination with pembrolizumab for treating a cancer in a human individual by a method comprising administering to the individual (i) axitinib formulated as a 1 mg tablet or a 5 mg tablet and pembrolizumab formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab or (ii) axitinib formulated as a 1 mg tablet or a 5 mg tablet and pembrolizumab formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab.

**Date 22 July 2016**

**MALATHI LAKSHMIKUMARAN  
IN/PA- 1433  
AGENT FOR THE APPLICANTS**

**To  
The Controller of Patents  
The Patent Office, at New Delhi**

I/We Claim:

1. A medicament comprising an antagonist of a Programmed Death 1 protein (PD-1) for use in combination with a vascular endothelial growth factor receptor (VEGFR) inhibitor for treating a cancer in an individual, wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO:21 and SEQ ID NO:22, respectively, and further wherein the VEGFR inhibitor is N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide or a pharmaceutically acceptable salt thereof.
2. A medicament comprising a vascular endothelial growth factor receptor (VEGFR) inhibitor for use in combination with an antagonist of a Programmed Death 1 protein (PD-1) for treating a cancer in an individual, wherein the VEGFR inhibitor is N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide or a pharmaceutically acceptable salt thereof, and further wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO:21 and SEQ ID NO:22.
3. The medicament ~~as claimed in~~ claim 1 or 2, wherein the individual is a human.
4. The medicament ~~as claimed in~~ any one of claims 1 to 3, wherein the cancer is a solid tumor that tests positive for Programmed Death-Ligand 1 (PD-L1) expression by an immunohistochemical (IHC) assay.
5. The medicament ~~as claimed in~~ any one of claims 1 to 3, wherein the cancer is renal cell carcinoma.

6. The medicament as claimed in ~~of~~ any one of claims 1 to 5, wherein the PD-1 antagonist is pembrolizumab and the VEGFR inhibitor is axitinib.
7. The medicament as claimed in ~~of~~ claim 6, wherein the pembrolizumab is formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab, 7% (w/v) sucrose, 0.02% (w/v) polysorbate 80 in 10 mM histidine buffer pH 5.5 and axitinib is formulated as a 1 mg tablet or a 5 mg tablet.
8. A kit which comprises a first container, a second container and a package insert, wherein the first container comprises at least one dose of a medicament comprising an antagonist of a Programmed Death 1 protein (PD-1), the second container comprises at least one dose of a medicament comprising a vascular endothelial growth factor receptor (VEGFR) inhibitor, and the package insert comprises instructions for treating an individual for cancer using the medicaments, wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO:21 and SEQ ID NO:22, respectively, and further wherein the VEGFR inhibitor is N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide or a pharmaceutically acceptable salt thereof.
9. The kit as claimed in ~~of~~ claim 8, wherein the instructions state that the medicaments are intended for use in treating an individual having a cancer that tests positive for Programmed Death-Ligand 1 (PD-L1) expression by an immunohistochemical (IHC) assay.
10. The kit as claimed in ~~of~~ claim 8 or 9, wherein the individual is a human.

11. The kit as claimed in ~~of~~ any one of claims 8 to 10, wherein the PD-1 antagonist is pembrolizumab formulated as a liquid medicament and the VEGFR inhibitor is axitinib formulated as a 1 mg tablet or a 5 mg tablet.
12. The use or kit as claimed in ~~of~~ any one of claims 1-4 or 6-10, wherein the cancer is bladder cancer, breast cancer, clear cell kidney cancer, head/neck squamous cell carcinoma, lung squamous cell carcinoma, malignant melanoma, non-small-cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, small-cell lung cancer (SCLC), triple negative breast cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin's lymphoma (HL), mantle cell lymphoma (MCL), multiple myeloma (MM), myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), non-Hodgkin's lymphoma (NHL), or small lymphocytic lymphoma (SLL).
13. The use or kit as claimed in ~~of~~ any one of the above claims, wherein the cancer is advanced renal cell carcinoma.
14. A medicament comprising:
  - a) pembrolizumab for use in combination with axitinib for treating a cancer in a human individual by a method comprising administering to the individual
    - (i) axitinib formulated as a 1 mg tablet or a 5 mg tablet ~~at a dose of 5 mg twice daily (BID)~~ and pembrolizumab formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab ~~at a dose selected from the group consisting of 1 mg/kg every three weeks (Q3W), 2 mg/kg Q3W and 200 mg Q3W~~ or
    - (ii) axitinib formulated as a 1 mg tablet or a 5 mg tablet ~~at a dose of 3 mg BID~~ and pembrolizumab formulated as a liquid medicament which

~~comprises 25 mg/ml pembrolizumab at a dose selected from the group consisting of 1 mg/kg Q3W, 2 mg/kg Q3W and 200 mg Q3W; or~~

- b) axitinib for use in combination with pembrolizumab for treating a cancer in a human individual by a method comprising administering to the individual
- (i) axitinib ~~formulated as a 1 mg tablet or a 5 mg tablet at a dose of 5 mg BID~~ and pembrolizumab ~~formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab at a dose selected from the group consisting of 1 mg/kg Q3W, 2 mg/kg Q3W and 200 mg Q3W~~ or (ii) axitinib ~~formulated as a 1 mg tablet or a 5 mg tablet at a dose of 3 mg BID~~ and pembrolizumab ~~formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab at a dose selected from the group consisting of 1 mg/kg Q3W, 2 mg/kg Q3W and 200 mg Q3W.~~